An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)

Alberto D'Angelo, Stefan Bagby, Giulia Di Pierro, Martina Chirra, Stefania Nobili, Enrico Mini, Donata Villari, Giandomenico Roviello

Research output: Contribution to journalReview article

1 Citation (Scopus)
2 Downloads (Pure)

Abstract

Patients diagnosed with non-clear renal cell carcinoma have often been excluded from clinical trials due to the shortage of treatments available, the low incidence of tumours with non-clear histology, and the corresponding diversity of intrinsic molecular features. This approach led to a knowledge gap in finding the optimal treatment for patients diagnosed with non-clear cell renal carcinoma. Cabozantinib, a potent multiple tyrosine kinase receptor inhibitor, has been recently investigated in patients with non-clear cell histologies of renal cell cancer. In this review, we have summarized available data on the use of cabozantinib in non-clear renal cell carcinoma.

Original languageEnglish
Article number102921
JournalCritical Reviews in Oncology/Hematology
Volume149
Early online date3 Mar 2020
DOIs
Publication statusPublished - May 2020

Keywords

  • Anilides/therapeutic use
  • Antibodies, Monoclonal/therapeutic use
  • Antineoplastic Agents/therapeutic use
  • Carcinoma, Renal Cell/drug therapy
  • Disease-Free Survival
  • Humans
  • Kidney Neoplasms/drug therapy
  • Protein Kinase Inhibitors
  • Pyridines/therapeutic use

Fingerprint Dive into the research topics of 'An overview of the clinical use of cabozantinib in the treatment of advanced non-clear-cell renal cell carcinoma (NCCRCC)'. Together they form a unique fingerprint.

Cite this